Brain injury is the most common intracranial injury in human cerebrovascular disease, which may lead to ischemic stroke. Resveratrol induces ameliorative effects in the treatment of certain human diseases by regulating different signaling pathways. The present study assessed the therapeutic effects of resveratrol and its potential mechanism of action in the neurons from rats with ischemia/reperfusion-induced cerebral hemorrhage. The rat model of cerebral hemorrhage was established and reverse transcription-quantitative polymerase chain reaction, western blotting, immunohistochemistry and terminal deoxynucleotidyl-transferase-mediated dUTP nick end labeling assays were subsequently performed to assess the therapeutic effects of resveratrol. The results demonstrated that treatment with resveratrol (10 mg/kg/day) decreased cerebral water content, hippocampal cell apoptosis and cerebral infarct volume compared with the PBS-treated group. Resveratrol treatment also increased neuronal cell viability, improved neurological function and blood brain barrier disruption compared with the PBS group following 21 days of treatment. The administration of resveratrol was demonstrated to decrease the levels of certain inflammatory factors, including ionized calcium binding adaptor molecule 1 and myeloperoxidase, in rats with cerebral hemorrhage. The results revealed that treatment with resveratrol regulated neuronal apoptosis by downregulating the transforming growth factor-β (TGF-β)-mediated extracellular signal-regulated kinase (ERK) signaling pathway. In conclusion, these results indicate that resveratrol decreases ischemia/reperfusioninduced neuronal apoptosis by downregulating the TGF-β-mediated ERK pathway in a rat model of cerebral hemorrhage and may serve as a potential agent for the treatment of cerebral hemorrhage.
Introduction
Cerebral hemorrhage is a type of human cardiovascular system disease, which serves an important adjunct role in primary brain injury and often leads to vasospasm (1) . A previous systematic review and meta-analysis has indicated that intracranial hemorrhage increases the risk of cerebral microbleeds in patients with acute stroke (2) . Cerebrovascular injury is frequently caused by ischemia/reperfusion, which may lead to cerebral infarct and neuronal apoptosis (3) . Additionally, the inhibition of neuronal apoptosis is beneficial for the recovery of cognitive disorders in cerebral hemorrhage induced by ischemia/reperfusion (4) . Therefore, understanding the apoptosis of neurons is essential for the treatment of cerebral hemorrhage.
Resveratrol is a multifunctional biological polyphenol that serves therapeutic effects in certain types of human disease (5) . A previous study has indicated that the neuroprotective effects of resveratrol in ischemic injury are mediated by the improvement of brain energy metabolism and the alleviation of oxidative stress in rats (6) . Zou et al (7) have revealed that the continuous infusion of resveratrol over a 4-week period protected neurons from cannulae implantation injury. In addition, pre-treatment with resveratrol attenuated traumatic brain injury in rats by suppressing NACHT, LRR and PYD domains-containing protein 3 inflammasome activation via sirtuin 1 (7) . Furthermore, resveratrol also ameliorated hypoxia/ischemia-induced behavioral deficits and brain injury in the neonatal rat brain (8) . A previous study has also demonstrated that the decreased expression of the transforming growth factor-β (TGF-β) gene superfamily is associated with adult neurogenic regions following brain injury (9) . However, associations between resveratrol and TGF-β have not yet been reported in neurons.
The present study assessed the therapeutic role of resveratrol in a rat model of cerebral hemorrhage. Cerebral infarct volume, hippocampal cell apoptosis and neuron viability were analyzed following a 21-day experimental period. Notably, the present study assessed the association between resveratrol and the TGF-β-mediated extracellular signal-regulated kinase (ERK) signaling pathway in neurons isolated from a rat model of cerebral hemorrhage.
Materials and methods
Rat model of cerebral hemorrhage. A total of 16 male Sprague-Dawley rats (weight, 300-330 g; age, 8 weeks) were purchased from Harbin Veterinary Research Institute (Harbin, China). All rats were housed at a temperature of 23±1˚C and humidity of 50±5%, with a 12-h light/dark cycle and free access to food and water. The rat model of cerebral hemorrhage was established using the modified ischemia/reperfusion method as previously described (10) . Rats received right middle cerebral artery occlusion for 90 min and reperfusion by withdrawal of the filament at 37˚C Immediately, rats with ischemia/reperfusion-induced cerebrovascular injury were randomly divided into two groups (each, n=8) and were administered an intravenous injection of resveratrol (10 mg/kg/day; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) or the same volume of PBS (serving as the control) as described previously (11) . The treatments were continued for 20 days. Rats were sacrificed using cervical dislocation following intraperitoneal pentobarbital injection (35 mg/kg body weight) on day 21 for further analysis.
Behavioral tests. Behavioral function (locomotor activity) was examined in experimental rats using open-field tests on day 21. These were used to analyze the efficacy of resveratrol on ischemia/reperfusion injury and were performed as previously described (12) .
Cell culture. Rats were sacrificed via cervical dislocation. Neuronal cells were isolated from rats with cerebral hemorrhage prior to treatment as described previously (13) . Cells were cultured in RPMI 1640 medium (Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Thermo Fisher Scientific, Inc.) for 24 h at 37˚C. Cells were then treated with a TGF-β inhibitor (TGF-βIR; 2 mg/ml; Sigma-Aldrich; Merck KGaA) or TGF-β and/or resveratrol (2 mg/ml; Sigma-Aldrich; Merck KGaA) for 24 h at 37˚C.
Analysis of cerebral water content (CWC)
. On day 21, CWC was evaluated in the resveratrol and PBS group as described in a previous study (14) . Rat brains were isolated as detailed previously (15) . Brains were dried in an electric oven at 100˚C for 24 h to analyze CWC in the rat model of intracerebral hemorrhage. The CWC was calculated using the following formula: (wet weight-dry weight/wet weight) x100 (%).
Quantitative analysis of blood-brain barrier (BBB) permeability. BBB leakage was examined as previously described (16) . Briefly, experimental rats received 100 µl 5% Evan's blue with resveratrol or PBS administered intravenously 10 days following ischemia/reperfusion-induced injury. Following the injection of Evan's blue (for 2 h), cardiac perfusion was performed under deep anesthesia with 200 ml of saline to clear the cerebral circulation of Evan's blue. Brains were subsequently isolated and sliced. The two hemispheres were homogenized in 750 µl of N,N-dimethylformamide (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Quantitative analysis of blood-brain barrier permeability was performed using Evan's blue and absorbance was measured at 689 nm using a microplate reader.
Cell viability assay. Neuron cell viability was determined using an MTT assay kit (cat. no. M6494; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. Neuronal cells (1x10 3 cells/well) were seeded in 96-well plates and cultured in RPMI 1640 medium supplemented with 10% FBS at 37˚C for 22 h. Following incubation, 15 µl MTT reagent was added to each well and incubated for a further 4 h. Following incubation, DMSO (150 µl) was added to each well to dissolve the purple formazan. Cell viability was determined by measuring the absorbance was measured at a wavelength of 570 nm using a microplate reader.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. Total RNA was extracted from neuronal cells using an RNAeasy Mini kit (Qiagen Sciences, Inc., Gaithersburg, MD, USA) according to the manufacturer's protocol. RNA was reverse transcribed into cDNA at 42˚C for 2 h using the High Capacity cDNA Reverse Transcription kit (Thermo Fisher Scientific, Inc.). PCR amplification involved preliminary denaturation at 95˚C for 1 min, followed by 45 cycles of 95˚C for 30 sec. The annealing temperature was reduced to 57˚C for 30 sec and 72˚C for 10 min. The reaction volume was a total of 20 µl containing 40 ng genomic cDNA, 100 µM dNTPs, 200 µM primers and Taq DNA polymerase and SYBR-Green (each, 2.5 U; Thermo Fisher Scientific, Inc.). The forward and reverse primers were synthesized by Invitrogen (Thermo Fisher Scientific, Inc.) and are listed in Table I . Relative mRNA expression levels were calculated using the 2 -ΔΔCq method (17) .
Western blotting. On day 21, TGF-β, TGF-βIR and/or resveratrol-treated neurons were lysed using radioimmunoprecipitation buffer containing protease inhibitors (Thermo Fisher Scientific, Inc.) at 4˚C for 10 min. Protein concentration was measured using a bicinchoninic acid assay kit (Thermo Fisher Scientific, Inc.). Total protein (30 µg/lane) was separated via SDS-PAGE on 15% gels. The separated proteins were then transferred to polyvinylidene difluoride membranes (EMD Millipore, Billerica, MD, USA) and incubated in blocking buffer (5% bovine serum albumin; Sigma-Aldrich; Merck KGaA) for 2 h at 37˚C. Membranes were incubated with the primary antibodies against TGF-β Immunocytochemistry. Neuronal cells (1x10 6 ) were fixed in 10% formaldehyde for 30 min at 37˚C. Cells were permeabilized with 0.5% Triton X-100 in PBS for 5 min at 25˚C. Endogenous peroxidase activity was blocked using 3% hydrogen peroxide for 10 min at room temperature as previously described (18) . Subsequently, cells were incubated with specific primary antibodies against Iba-1 (1:1,200; cat. no. ab108539; Abcam) or MPO (1:1,200; cat. no. ab208670; Abcam) for 12 h at 4˚C. Cells were washed with PBS and subsequently incubated with anti-rabbit HRP-conjugated secondary antibody (1:2,000; cat. no. ab191866; Abcam) for 12 h at 4˚C. Cells were subsequently washed with PBS three times and incubated with 5% DAPI (Sigma-Aldrich; Merck KGaA) for 15 min at 37˚C. Cells were observed under a fluorescent microscope (magnification, x40; Olympus Corporation, Tokyo, Japan). The percentage of positively stained cells was analyzed using Quantity One software (version 4.62; Bio-Rad Laboratories, Inc.).
Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay. Cells obtained from the rat model of cerebral hemorrhage were analyzed using a TUNEL assay (DeadEnd™ Colorimetric Tunel System; Promega Corporation, Madison, WI, USA) according to the manufacturer's protocol. Cells were then incubated with 5% DAPI (Sigma-Aldrich; Merck KGaA) for 15 min at 37˚C and washed with PBS three times and mounted onto slides using Aqueous Mounting Medium (Sigma-Aldrich; Merck KGaA). TUNEL-positive cells were observed in three randomly-selected fields under a ZEISS LSM 510 confocal microscope (Zeiss GmbH, Jena, Germany) at 488 nm.
Statistical analysis. Data are presented as the mean ± standard deviation of triplicate data. All data were analyzed using SPSS 19.0 software (SPSS, IBM Corp., Armonk, NY, USA). Significant differences between two groups were analyzed using a two-tail unpaired Student's t-test. Multiple group differences were analyzed using one-way analysis of variance followed by a Tukey's HSD test. P<0.05 was considered to indicate a statistically significant difference.
Results

Resveratrol decreases cerebral infarct volume and improves cognitive competence in the rat model of cerebral hemorrhage.
The therapeutic effects of resveratrol were analyzed in a rat model of cerebral hemorrhage. The viability assay demonstrated that treatment with resveratrol significantly increased neuronal cell viability in hippocampus tissue compared with the PBS group (Fig. 1A) . It was also revealed that resveratrol significantly decreased cerebral infarct volume in the hippocampi of rats with cerebral hemorrhage compared with the PBS group (Fig. 1B) . Furthermore, treatment with resveratrol significantly increased the escape latency of rats compared with the PBS group (Fig. 1C ). It was also demonstrated that the body weight of resveratrol-treated rats increased significantly compared with the PBS group (Fig. 1D) . These results suggest that resveratrol may be an efficient drug for the treatment of cerebral hemorrhage.
Resveratrol improves CWC and BBB disruption in the rat model of cerebral hemorrhage.
The results demonstrated that treatment with resveratrol significantly decreased and improved CWC and BBB disruption, respectively, when compared with the PBS group ( Fig. 2A-B ). Furthermore, treatment with resveratrol significantly increased microglial activation and neutrophil infiltration as determined by Iba-1and MPO-positive cells, respectively (Fig. 2C-D) . These results indicate that resveratrol was beneficial for the inhibition of the inflammatory response in the brain of mice with cerebral hemorrhage.
Treatment with resveratrol decreases neuronal cell apoptosis and inflammation. The apoptosis of neurons was assessed following treatment with resveratrol in the TUNEL assay. The results indicated that resveratrol significantly decreased neuronal apoptosis in rats with cerebral hemorrhage (Fig. 3A) . Anti-apoptotic gene and protein expression (Bcl-2 and Bcl-xl) was significantly upregulated, and pro-apoptotic gene and protein levels (Bad and Bax) were significantly downregulated by treatment with resveratrol, compared with the control (Fig. 3B-C) . It was also revealed that treatment with resveratrol significantly increased the expression levels of anti-inflammatory factors Iba-1 and MPO in neurons ( Fig. 3D-E) . These results indicate that resveratrol decreased neuronal cell apoptosis and inflammation in rats with cerebral hemorrhage. Resveratrol regulates neuronal cell apoptosis by regulating the TGF-β-mediated ERK signaling pathway. The current study analyzed the potential resveratrol-mediated mechanism of apoptosis and inflammation in neuron cells. It was demonstrated that resveratrol significantly downregulated TGF-β and ERK gene and protein expression in neurons isolated from rats with cerebral hemorrhage (Fig. 4A-B) . Treatment with TGF-βIR downregulated TGF-β and ERK gene and protein expression levels in neurons ( Fig. 4C-D) . Resveratrol-TGF-β treatment increased the protein expression levels of ERK/pERK compared with TGFβ treatment alone (Fig. 4E ). In addition, resveratrol-TGF-β treatment significantly decreased the number of TUNEL positive cells compared with TGF-β treatment (Fig. 4F) The results indicated that treatment with TGF-β reversed the decrease in neuronal cell apoptosis induced by resveratrol (Fig. 4F) . These results suggest that resveratrol decreased apoptosis by downregulating the TGF-β-mediated ERK signaling pathway.
Discussion
Neuronal apoptosis serves a crucial role in the progression of brain injury (19) . A previous study has demonstrated that resveratrol prevents neuronal apoptosis in an early brain injury model through the phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) signaling pathway (20) . The current study assessed the therapeutic effects of resveratrol in a rat model of cerebral hemorrhage induced by reperfusion injury and further analyzed the potential mechanism of resveratrol in neuronal cells. The results demonstrated that resveratrol decreased apoptosis and inflammation in rats of the hippocampal reperfusion injury model. The results also indicated that resveratrol inhibited hippocampal cell apoptosis and inflammation by downregulating the of TGF-β-ERK signaling pathway. Evidence has indicated that the inhibition of neural apoptosis attenuated early brain injury induced by subarachnoid hemorrhage (21) . A previous study has demonstrated that resveratrol inhibited b-amyloid-induced neuronal apoptosis by regulating the acetylation of cellular tumor antigen p53 in PC12 cells (22) . It has also been indicated that increasing the activity of the Bak signaling pathway may mediate apoptosis in cultured neural progenitor cells (23) . In the current study, treatment with resveratrol inhibited hippocampal cell apoptosis by decreasing the expression of Bad and Bax in neurons. Additionally, treatment with resveratrol upregulated anti-apoptotic Bcl-2 and Bcl-xl protein levels, which may be the reason for the resveratrol-induced decrease of apoptosis in neurons.
Previous studies have revealed that TGF-β promotes recovery following intracerebral hemorrhage, indicating that TGF-β may be a therapeutic target for the treatment of acute brain injury (24) . The current study demonstrated that treatment with resveratrol decreased the expression of TGF-β, which further led to the decrease of neuronal cells apoptosis. A further study has revealed that ERK serves a protective role in the apoptotic mechanisms involved in sympathetic neuron survival (25) . The results of the present study demonstrated that treatment with resveratrol inhibits hippocampal cell apoptosis by downregulating the TGF-β-mediated ERK signaling pathway. Li et al (18) revealed that nerve growth factor attenuates high glucose-induced endoplasmic reticulum stress, which prevents Schwann cells from undergoing apoptosis by activating the PI3K/Akt/glycogen synthase kinase-3 β and ERK1/2 signaling pathways. Notably, the present study demonstrated that treatment with resveratrol decreased cerebral infarct volume and CWC. It also improved cognitive competence and BBB disruption in the rat model of cerebral hemorrhage. However, the current study did not assess the effects of an ERK inhibitor on resveratrol-treated brain injury. Further study is therefore required to analyze the role of an ERK inhibitor on the resveratrol-induced decrease of hippocampal cell apoptosis in cerebral hemorrhage.
In conclusion, the current study assessed the therapeutic effects of resveratrol in hippocampal cells of rats with cerebral hemorrhage. The results revealed that treatment with resveratrol inhibited neuronal cell apoptosis by downregulating the TGF-β-mediated ERK signaling pathway in rats with cerebral hemorrhage. These results indicate that resveratrol may be a potential drug for the treatment of cerebral hemorrhage induced by ischemic reperfusion.
